Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Purchases 30,000 Shares of Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were purchased at an average price of $2.03 per share, with a total value of $60,900.00. Following the completion of the acquisition, the director owned 416,904 shares of the company’s stock, valued at $846,315.12. This represents a 7.75% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Jr. Baltera also recently made the following trade(s):

• On Monday, July 6th, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were purchased at an average cost of $2.05 per share, with a total value of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was acquired at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

Shares of NASDAQ:PALI opened at $2.05 on Thursday. The company’s 50-day moving average price is $1.92 and its two-hundred day moving average price is $1.92. Palisade Bio, Inc. has a one year low of $0.53 and a one year high of $2.86. The stock has a market capitalization of $355.84 million, a PE ratio of -2.03 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, analysts anticipate that Palisade Bio, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of Palisade Bio

Several large investors have recently made changes to their positions in PALI. Commodore Capital LP acquired a new stake in shares of Palisade Bio in the 4th quarter valued at $26,896,000. BIT Capital GmbH acquired a new stake in Palisade Bio in the fourth quarter valued at about $717,000. Creek Drive Management Group LLC acquired a new stake in Palisade Bio in the fourth quarter valued at about $723,000. Perceptive Advisors LLC bought a new position in Palisade Bio in the fourth quarter valued at about $28,318,000. Finally, Artia Global Partners LP acquired a new position in Palisade Bio during the fourth quarter worth about $4,682,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio News Roundup

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
• Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
• Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
• Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing

Analysts Set New Price Targets

Several research firms have issued reports on PALI. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a research note on Tuesday, June 30th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 29th. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Oppenheimer set a $7.00 price objective on Palisade Bio in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.